Prevalenza di anticorpi anticardiolipina e/o anticorpi anti beta 2 glicoproteina I in pazienti con epilessia

M. Viri; R. Cimaz; A. Scarano; M. Lodi; A. Gatti; P. Veggiotti; P. L. Meroni; A. Romeo

Prevalenza di anticorpi anticardiolipina e/o anticorpi anti beta 2 glicoproteina I in pazienti con epilessia

Translated title of the contribution: High prevalence of anticardiolipin and/or anti-β2 glycoprotein I antibodies in young patients with epilepsy

M. Viri, R. Cimaz, A. Scarano, M. Lodi, A. Gatti, P. Veggiotti, P. L. Meroni, A. Romeo

Research output: Contribution to journal › Article › peer-review

Abstract

Previous studies have suggest that anticardiolipin (aCL) antibodies can be associated with epilepsy in patients with SLE. We started a prospective study in order to determine the prevalence of aCL and anti-beta2 glycoprotein 1 (beta2-GPI) antibodies in sera of 142 patients with pediatric-onset epilepsy, without signs of autoimmunological diseases. Positive results were found in 44/142 cases (31%). We conclude that aCl and anti-beta2-GPI can be associated with epilepsy even in patients without SLE.

Translated title of the contribution	High prevalence of anticardiolipin and/or anti-β2 glycoprotein I antibodies in young patients with epilepsy
Original language	Italian
Pages (from-to)	213-214
Number of pages	2
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	106-107
Publication status	Published - 1999

ASJC Scopus subject areas

Clinical Neurology

Cite this

@article{b2663f54d2ea4b398f05df8fdc6e1098,

title = "Prevalenza di anticorpi anticardiolipina e/o anticorpi anti beta 2 glicoproteina I in pazienti con epilessia",

abstract = "Previous studies have suggest that anticardiolipin (aCL) antibodies can be associated with epilepsy in patients with SLE. We started a prospective study in order to determine the prevalence of aCL and anti-beta2 glycoprotein 1 (beta2-GPI) antibodies in sera of 142 patients with pediatric-onset epilepsy, without signs of autoimmunological diseases. Positive results were found in 44/142 cases (31%). We conclude that aCl and anti-beta2-GPI can be associated with epilepsy even in patients without SLE.",

keywords = "Antiphospholipid antibodies-epilepsy-childhood",

author = "M. Viri and R. Cimaz and A. Scarano and M. Lodi and A. Gatti and P. Veggiotti and Meroni, {P. L.} and A. Romeo",

year = "1999",

language = "Italian",

pages = "213--214",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "106-107",

}

TY - JOUR

T1 - Prevalenza di anticorpi anticardiolipina e/o anticorpi anti beta 2 glicoproteina I in pazienti con epilessia

AU - Viri, M.

AU - Cimaz, R.

AU - Scarano, A.

AU - Lodi, M.

AU - Gatti, A.

AU - Veggiotti, P.

AU - Meroni, P. L.

AU - Romeo, A.

PY - 1999

Y1 - 1999

N2 - Previous studies have suggest that anticardiolipin (aCL) antibodies can be associated with epilepsy in patients with SLE. We started a prospective study in order to determine the prevalence of aCL and anti-beta2 glycoprotein 1 (beta2-GPI) antibodies in sera of 142 patients with pediatric-onset epilepsy, without signs of autoimmunological diseases. Positive results were found in 44/142 cases (31%). We conclude that aCl and anti-beta2-GPI can be associated with epilepsy even in patients without SLE.

AB - Previous studies have suggest that anticardiolipin (aCL) antibodies can be associated with epilepsy in patients with SLE. We started a prospective study in order to determine the prevalence of aCL and anti-beta2 glycoprotein 1 (beta2-GPI) antibodies in sera of 142 patients with pediatric-onset epilepsy, without signs of autoimmunological diseases. Positive results were found in 44/142 cases (31%). We conclude that aCl and anti-beta2-GPI can be associated with epilepsy even in patients without SLE.

KW - Antiphospholipid antibodies-epilepsy-childhood

UR - http://www.scopus.com/inward/record.url?scp=0033493502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033493502&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033493502

SN - 0394-560X

SP - 213

EP - 214

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

IS - 106-107

ER -

Prevalenza di anticorpi anticardiolipina e/o anticorpi anti beta 2 glicoproteina I in pazienti con epilessia

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this